Inovio Pharmaceuticals Inc
NASDAQ:INO

Watchlist Manager
Inovio Pharmaceuticals Inc Logo
Inovio Pharmaceuticals Inc
NASDAQ:INO
Watchlist
Price: 4.01 USD -2.91% Market Closed
Market Cap: 104.1m USD
Have any thoughts about
Inovio Pharmaceuticals Inc?
Write Note

Inovio Pharmaceuticals Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Inovio Pharmaceuticals Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Inovio Pharmaceuticals Inc
NASDAQ:INO
Total Current Liabilities
$23.5m
CAGR 3-Years
-23%
CAGR 5-Years
4%
CAGR 10-Years
10%
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$43.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$11.7B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$20.3B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$4B
CAGR 3-Years
28%
CAGR 5-Years
23%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.7B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
24%
No Stocks Found

Inovio Pharmaceuticals Inc
Glance View

Market Cap
104.5m USD
Industry
Biotechnology

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 317 full-time employees. The firm is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The firm's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.

INO Intrinsic Value
5.93 USD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Inovio Pharmaceuticals Inc's Total Current Liabilities?
Total Current Liabilities
23.5m USD

Based on the financial report for Sep 30, 2024, Inovio Pharmaceuticals Inc's Total Current Liabilities amounts to 23.5m USD.

What is Inovio Pharmaceuticals Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
10%

Over the last year, the Total Current Liabilities growth was -46%. The average annual Total Current Liabilities growth rates for Inovio Pharmaceuticals Inc have been -23% over the past three years , 4% over the past five years , and 10% over the past ten years .

Back to Top